SHR-A1904 Compared With Investigator's Choice of Therapy in Claudin18.2 Positive Patitens With Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Progression-free survival (PFS) by investigator assessment

Measure description: Defined as time from randomization until progression or death as assessed by the investigator

Time frame: Until progression or death, assessed up to approximately 1 year

Objective response rate (ORR) by investigator assessment

Measure description: Defined as percentage of participants who achieved a best overall response of complete response (CR) or partial response (PR) assessed by the investigator

Time frame: Until progression, assessed up to approximately 1 year

Duration of response (DOR) by investigator assessment

Measure description: Defined as the time from the first documented objective response (CR or PR) to the first documented disease progression or death assessed by the investigator

Time frame: Until progression or death, assessed up to approximately 1 year

Disease control rate (DCR) by investigator assessment

Measure description: Defined as percentage of participants who achieved a best overall response of complete response (CR), partial response (PR) or stable disease (SD) assessed by the investigator

Time frame: Until progression, assessed up to approximately 1 year

Incidence and severity of adverse events (AEs)/serious adverse events (SAEs)

Measure description: Incidence and severity of adverse events (AEs)/serious adverse events (SAEs) graded by Common Terminology Criteria for Adverse Events (CTCAE) v5.0